细胞周期进展评分而非磷酸酶及张力蛋白同源物缺失是接受或不接受挽救性放疗的中危和高危前列腺癌患者转移的独立预后因素
在209例中危/高危前列腺癌根治术患者(病例队列)和172例接受挽救性放疗的同类患者中,细胞周期进展评分与无转移生存独立相关(风险比分别为3.11和1.85),而磷酸酶及张力蛋白同源物缺失在校正术后前列腺癌风险评估后不再显著。
要点
- 细胞周期进展评分是中危/高危前列腺癌根治术后转移的独立预后因素。
- 磷酸酶及张力蛋白同源物缺失在校正术后前列腺癌风险评估后无统计学意义。
- 细胞周期进展评分在不良中危组中效应最强。
核心结论
- 在仅中危/高危前列腺癌患者及接受挽救性放疗的此类患者中,细胞周期进展评分而非磷酸酶及张力蛋白同源物缺失与转移风险显著增加2至3倍相关(校正术后前列腺癌风险评估后)。
研究设计与样本
- 病例队列研究纳入209例中危/高危前列腺癌根治术患者,另纳入172例接受挽救性放疗的同类患者;细胞周期进展评分由RNA表达计算,磷酸酶及张力蛋白同源物通过免疫组化分析。
- 采用比例风险回归(病例队列设计加权,挽救性放疗队列未加权)评估细胞周期进展评分和磷酸酶及张力蛋白同源物与无转移生存的关联;用一致性指数评估模型区分度改善。
主要发现
- 病例队列中41例发生转移,挽救性放疗队列中17例发生转移,中位随访分别为3年和4年。
- 病例队列中,校正术后前列腺癌风险评估后,细胞周期进展评分与无转移生存独立相关,风险比=3.11(95%置信区间1.70-5.69)。
- 挽救性放疗队列中,校正术后前列腺癌风险评估后,细胞周期进展评分与无转移生存独立相关,风险比=1.85(95%置信区间1.19-2.85)。
- 将细胞周期进展评分加入术后前列腺癌风险评估后,病例队列的一致性指数从0.861升至0.899,挽救性放疗队列从0.745升至0.819。
- 磷酸酶及张力蛋白同源物在单变量分析中有统计学意义,但校正术后前列腺癌风险评估后不再显著。
关键数值与推荐
- 与全国综合癌症网络风险组的交互分析显示,细胞周期进展评分在不良中危男性中效应最强。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The prognostic value for metastasis of the cell-cycle progression score and phosphatase and tensin homolog haven't been evaluated jointly in contemporary men with exclusively intermediate- or high-risk prostate cancer. We evaluated associations of cell-cycle progression and phosphatase and tensin homolog with metastasis-free survival in contemporary intermediate/high-risk prostate cancer patients overall, and intermediate/high-risk men receiving salvage radiotherapy. MATERIALS AND METHODS: In a case-cohort of 209 prostatectomy patients with intermediate/high-risk prostate cancer, and a cohort of 172 such men who received salvage radiotherapy, cell-cycle progression score was calculated from RNA expression, and phosphatase and tensin homolog was analyzed by immunohistochemistry. Proportional hazards regression, weighted for case-cohort design or unweighted for the salvage radiotherapy cohort, was used to evaluate associations of cell-cycle progression, phosphatase and tensin homolog with metastasis-free survival. Improvement in model discrimination was evaluated with the concordance index. RESULTS: In the case-cohort 41 men had metastasis, and 17 developed metastasis in the salvage radiotherapy cohort, at median follow-up of 3 and 4 years, respectively. For both case-cohort and salvage radiotherapy cohort, cell-cycle progression was independently associated with metastasis-free survival after adjustment for Cancer of the Prostate Risk Assessment Post-Surgical: hazard ratio (95% confidence interval) = 3.11 (1.70-5.69) and 1.85 (1.19-2.85), respectively. Adding cell-cycle progression to Cancer of the Prostate Risk Assessment Post-Surgical increased the concordance index from 0.861 to 0.899 (case-cohort), and 0.745 to 0.819 (salvage radiotherapy cohort). Although statistically significant in univariate analyses, phosphatase and tensin homolog was no longer significant after adjustment for Cancer of the Prostate Risk Assessment Post-Surgical. Analysis of interaction with National Comprehensive Cancer Network risk group showed that cell-cycle progression had the strongest effect among unfavorable intermediate-risk men. CONCLUSIONS: In the first study to evaluate metastasis risk associated with cell-cycle progression and phosphatase and tensin homolog in exclusively intermediate/high-risk prostate cancer, and in such men with salvage radiotherapy, cell-cycle progression but not phosphatase and tensin homolog was associated with significantly increased 2- to 3-fold risk of metastasis after Cancer of the Prostate Risk Assessment Post-Surgical adjustment.
引用
- Trock BJ, Jing Y, Mabey B, et al. Cell Cycle Progression Score, but Not Phosphatase and Tensin Homolog Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-risk Prostate Cancer in Men Treated With and Without Salvage Radiotherapy. J Urol. 2022. PMID: 36006048. doi:10.1097/JU.0000000000002922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。